Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
l-glucose is the L-enantiomer of glucose, an aldohexose monosaccharide that is the mirror image of naturally occurring d-glucose and shares the same chemical formula C6H12O6 but opposite stereochemistry at all chiral centers.[1][3] It is not appreciably metabolized by human cells because it is not a substrate for hexokinase in glycolysis, making it effectively non-nutritive while retaining a sweet taste similar to d-glucose.[1] l-glucose has been investigated as a low-calorie sweetener suitable for people with diabetes, as an osmotic laxative and colon-cleansing agent before colonoscopy, and its derivative l-glucose pentaacetate has shown insulinotropic effects that could be relevant for type 2 diabetes therapy, but high production costs and lack of regulatory approvals have limited its development as a pharmaceutical or marketed food ingredient.[1][2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-glucose.